Article Figures & Data
Figures
- Figure 1.
Clinical outcome of patient CBI-0803 and response to anticancer agents in patient's xenografts. A, time course of CEA levels. B, tumor growth curve of patient's personalized tumorgraft, treated with the indicated agents at the dose and schedules. C and D, CT scan of the abdomen, before and after treatment with irinotecan-cetuximab and bevacizumab, showing a marked decrease in tumor volume. E, tumor growth curve of patient's tumor treated with the indicated agents.
- Figure 2.
Clinical outcome of patient CBI-0805 and remarkable antitumor potential of irinotecan in patient's xenografts. A, response of patient's tumorgraft to single-agent irinotecan illustrates a complete eradication of the tumor. B, CT scan of pelvis before treatment. C, CT scan of pelvis showing a significant reduction in a metastatic pelvic mass. D, intratumor concentration of irinotecan and SN38 in this patient's xenograft and an irinotecan-resistant colorectal cancer (CRC) tumorgraft (CRC-005), showing heightened retention of SN38 in CBI-0805.
Tables
- Table 1.
Patient characteristics and outcome of treatments based on xenograft predictions
Identification number Gender Age (years) Tumor Xenograft Prior systemic therapy Systemic therapy administered on the basis of xenograft data Response Duration of response (months) JH033 Male 63 Pancreatic ductal adenocarcinoma Primary tumor Gemcitabine Mitomycin C, cisplatin PR 50+ JH082 Female 64 Pancreatic ductal adenocarcinoma Primary tumor None Gemcitabine Progressive disease JH102 Female 66 Pancreatic ductal adenocarcinoma Primary tumor None Gemcitabine Stable disease JH161 Female 70 Pancreatic ductal adenocarcinoma Primary tumor None Gemcitabine Stable disease CBI-0601 Female 55 Leiomyosarcoma Pelvic metastasis Adriamycin, ifosfamide Gemcitabine, docetaxel, bevacizumab PR 9 Gemcitabine, doxetaxel Capcetabine, temozlomide PR 9 CBI-0602 Male 45 Mesenchymalchondro sarcoma Lung mestastasis VAC Docetaxel, irinotecan, bevacizumab PR 9 Sunitinib Stable disease 4 CBI-0603 Male 50 Non–small cell lung carcinoma Primary tumor Carboplatin, paclitaxel Sorafenib, irinotecan, bevacizumab PR 9 Pemetrexed No response CBI-0701 Male 36 Myoepithelioma Primary tumor None Doxorubicin, cisplatin Progressive disease Imatinib Progressive disease Carboplatin-bevacizumab Progressive disease CBI-0803 Male 54 Esophageal adenocarcinoma Liver metastasis Epirubicin, 5-fluorouracil, cisplatin Irinotecan-cetuximab- bevacizumab PR 14 Abraxane-avastin PR 9 Ixabepilone-avastin PR 9 Ixabepilone-navelbine PR 6+ CBI-0805 Female 44 Colon adenocarcinoma Liver metastasis FOLFOX Irinotecan PR 14 Capecitabine, lapatanib PR 6+ CBI-0810 Female 36 Breast cancer Liver metastasis 5-fluorouracil, cyclophosphamiirinotecan, bevacizumab None No response No response CBI-0901 Male 49 Rhabdomyosarcoma Lung metastasis None Docetaxel, gemcitabine, bevacizumab PR 8 CBI-0907 Female 62 Colon Liver metstasis FOLFOX Cetuximab, irinotecan PR 6 Irinotecan PR 15 CBI-0914 Male 58 Melanoma Lung metastasis None B-raf inhibitor PR 6 Note: When tumorgrafts reached approximately 150 mm3, animals were randomized (5 mice with tumors on both flanks per group) and dosing initiated. Details on drugs, doses, and schedules are provided in Supplementary Table S1.
Abbreviations: VAC, vinblastine, doxorubicin and cisplatin; FOLFOX, folinic acid, 5-fluorouracil, oxaliplatin.
Supplementary Data
Files in this Data Supplement:
Volume 10, Issue 8
